Navigation Links
Sinovac Presents at Two Investor Conferences in May 2011
Date:5/9/2011

BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor conferences in New York City.

  • Piper Jaffray 8th Annual China Growth Conference
  • Sinovac is scheduled to present at 4:00 pm on Tuesday, May 17, 2011 and will be participating in one-on-one meetings

  • A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .

  • Oppenheimer 5th Annual China Dragon Conference
  • Sinovac is scheduled to present at 8:30 am ET on Wednesday, May 18, 2011 and will be participating in one-on-one meetings on May 18

  • About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

    Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel:  +86-10-8279-9871/9659Fax:  +86-10-6296-6910Email: ir@sinovac.comInvestors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel:  +1-646-536-7025Email:  jrando@theruthgroup.com
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
    2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
    3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
    4. Sinovac Announces Plan to Launch Offering of Common Shares
    5. Sinovac Announces Recent Developments
    6. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
    7. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
    8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
    9. Sinovac Files Shelf Registration Statement
    10. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
    11. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
    (Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
    (Date:2/5/2016)... HARROGATE, England , February 5, 2016 ... --> Today, VoicePower Ltd - The Speech Recognition People, ... has been deployed to improve patient care, reduce turnaround times and ... ,- Wirral CCG ,- VoicePower client since 2013 Challenge: ... Challenge: --> - Six doctors ,- Wirral ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... San Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... partnership with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ... on New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder ...
    (Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... in gym use and find themselves having to wait longer to access the treadmills. ... on their New Year’s resolutions to lose weight and get in shape by joining ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
    (Date:2/5/2016)... ... 2016 , ... Stuart Bentkover, MD, FACS is thrilled to announce ... most effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts ... PicoSure has been approved by the Food and Drug Administration (FDA) as a safe ...
    (Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
    Breaking Medicine News(10 mins):